Leerink Partnrs Expects Stronger Earnings for Tourmaline Bio

Tourmaline Bio, Inc. (NASDAQ:TRML) – Leerink Partnrs increased their FY2025 EPS estimates for shares of Tourmaline Bio in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.56) per share for the year, up from their prior estimate of ($4.01). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.08) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($6.32) EPS and FY2028 earnings at ($7.22) EPS.

Tourmaline Bio (NASDAQ:TRML) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.06.

A number of other brokerages have also commented on TRML. BMO Capital Markets assumed coverage on shares of Tourmaline Bio in a research note on Friday, December 6th. They issued an “outperform” rating and a $50.00 price target on the stock. Guggenheim reiterated a “buy” rating on shares of Tourmaline Bio in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of Tourmaline Bio in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Tourmaline Bio in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $54.00.

Tourmaline Bio Price Performance

TRML stock opened at $21.81 on Friday. The stock has a market cap of $559.21 million, a price-to-earnings ratio of -7.73 and a beta of 2.32. The company has a fifty day moving average price of $26.02 and a two-hundred day moving average price of $19.82. Tourmaline Bio has a one year low of $12.12 and a one year high of $48.31.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new stake in Tourmaline Bio in the third quarter valued at about $8,701,000. Blue Owl Capital Holdings LP boosted its stake in shares of Tourmaline Bio by 18.5% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock valued at $22,060,000 after purchasing an additional 268,000 shares in the last quarter. State Street Corp grew its holdings in shares of Tourmaline Bio by 25.6% during the 3rd quarter. State Street Corp now owns 411,980 shares of the company’s stock valued at $10,592,000 after purchasing an additional 83,949 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Tourmaline Bio during the 2nd quarter worth approximately $909,000. Finally, Renaissance Technologies LLC lifted its stake in Tourmaline Bio by 184.9% in the 2nd quarter. Renaissance Technologies LLC now owns 100,076 shares of the company’s stock valued at $1,287,000 after purchasing an additional 64,950 shares during the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.